160 results on '"Bagci-Onder, Tugba"'
Search Results
2. Editorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization
3. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer
4. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
5. Directing chemiluminescent dioxetanes to mitochondria: A cationic luminophore enables in vitro and in vivo detection of cancer cells upon enzymatic activation
6. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis
7. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
8. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
9. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization
10. ACE2-Decorated Virus-Like Particles Effectively Block SARS-CoV-2 Infection.
11. Characterization and discrimination of spike protein in SARS‐CoV‐2 virus‐like particles via surface‐enhanced raman spectroscopy
12. HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex
13. Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate Cancer
14. Characterization and discrimination of spike protein in SARS‐CoV‐2 virus‐like particles via surface‐enhanced Raman spectroscopy.
15. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
16. The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme
17. Supplementary Figure 5 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
18. Data from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
19. Supplementary Figure 2 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
20. Supplementary Figure 3 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
21. Supplementary Figure 4 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
22. Supplementary Table Legends 1-5 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
23. Supplementary Figure 1 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
24. Neural Stem Cells as Therapeutic Delivery Vehicles for Malignant Brain Tumors
25. Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival
26. Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In Vivo
27. 3D bioprinted glioma models
28. Editorial: Cell Death and Targeted Cancer Therapies
29. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
30. Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia
31. Abstract 6255: CRISPRa-mediated induction of apoptosis in therapy-resistant glioblastoma cells via derepression of pro-apoptotic genes
32. Chronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibition
33. Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
34. Derivation of Neural Stem Cells from Mouse Induced Pluripotent Stem Cells
35. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells
36. Parameters Influencing Gene Delivery Efficiency of PEGylated Chitosan Nanoparticles: Experimental and Modeling Approach
37. IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
38. Abstract 3064: Investigation of ionizing radiation response in new resistance models of glioblastoma
39. Epigenetic Deregulation of Apoptosis in Cancers
40. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
41. Glioma-on-a-Chip Models
42. Stem Cell-Based Combination Therapies for Cancer
43. Neural Stem Cells as Therapeutic Delivery Vehicles for Malignant Brain Tumors
44. DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS
45. Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro and in vivo
46. The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
47. Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
48. Abstract PR05: Loss of PRC2 or KMT2D-COMPASS generates two quasi-mesenchymal cell states with distinct metastatic abilities
49. Combined inhibition of KDM6A/B and HDACs exacerbates integrated stress response and mediates therapeutic effects in IDH1-mutant glioma
50. EXTH-10. COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.